

Van: [CCMO - Bevoegde Instantie / Competent Authority](#)
Aan: [ccmo_frontoffice](#); [ccmo_eudract](#)
Onderwerp: FW: NL71107.056.19_CMHS552A12101 - Digital submission of amendment for notification
Datum: woensdag 28 juli 2021 10:00:55
Bijlagen: [A1_CMHS552A12101_Cover letter to CA NL71107.056.19.pdf](#)
[B7_CMHS552A12101_Declaration_end_of_trial_form.pdf](#)

= Einde studie

Van: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
Verzonden: woensdag 28 juli 2021 09:52
Aan: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
Onderwerp: FW: NL71107.056.19_CMHS552A12101 - Digital submission of amendment for notification

Van: [REDACTED] <[REDACTED]@novartis.com> Namens [REDACTED]
Verzonden: maandag 26 juli 2021 12:12
Aan: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
Onderwerp: NL71107.056.19_CMHS552A12101 - Digital submission of amendment for notification

Dear Madam, dear Sir,

On behalf of the Sponsor, **Novartis Pharma AG**, Parexel International Romania s.r.l. herewith submits a **notification** to the above-mentioned clinical trial.

The changes in this amendment relate to:

- **Declaration of the end of trial - Early termination**

We trust that the information provided in the application is sufficient, however if you require any further information, please contact us.

Yours faithfully,

[REDACTED] **on behalf of the applicant**
Parexel CTA Hub, [REDACTED]
Providing services for Novartis DRA under the CTA Regulatory Hub

Telephone: +40 [REDACTED]
E-mail: [REDACTED]@novartis.com